- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 90,590 | 03.07.24 13:43:57 | +0,170 | +0,19% | 90,540 | 90,590 | 90,890 | 90,420 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 976,000 | 03.07.24 10:04:17 | -5,600 | -0,57% | 975,000 | 986,600 | 976,000 | 981,600 |
